Borderline Endometrioid Adenocarcinoma of the Ovary Arising in Endometriosis During Tamoxifen Therapy of Postmenopausal Breast Cancer

**OBJECTIVE**: Tamoxifen has antiestrogenic activity and widely used to treat breast cancer. It also exerts weak estrogenic activity in postmenopausal women where estrogenic environment is low.

**Case Report**: A 75 year old woman receiving tamoxifen for her breast cancer developed a borderline endometrioid adenocarcinoma of the ovary arising in endometriosis is presented.

**Conclusion**: She was surgically staged as I C due to surgical rupture of the cyst. She is well and free of disease after five years.

**Key Words**: Tamoxifen, Borderline endometrioid adenocarcinoma, Ovary

T Klin J Gynecol Obst 2003, 13:152-154

Malignant transformation of endometriosis has been well documented by Sampson (1). Foci of endometriosis usually regress following menopause since estrogenic stimulus disappears. Estrogen replacement therapy may activate these foci. Tamoxifen is a well known unique drug which has antiestrogenic activity and is widely used to treat breast cancer. This drug competes with estrogens upon the level of receptors and has some weak estrogenic activity. It has been reported that it may induce endometrial hyperplasia, polyps, even cancer (2,3). Endometriosis has also been reported to develop in postmenopausal women with tamoxifen and recently two endometrioid carcinomas arisen in endometriosis during tamoxifen treatment have been reported (4,5).

This following is a case of borderline endometrioid adenocarcinoma arising from endometriosis of the ovary in a postmenopausal breast cancer patient treated with tamoxifen.

**Case Report**

A 75 year old woman, gravida 4, para 3, was referred to our department for unilateral adnexal mass. She had a right modified radical mastectomy for an infiltrating ductal carcinoma of a tumor 2 cm in size with no regional lymph node metastasis. Estrogen receptors were found to be positive. Tamoxifen (20 mg/day) therapy started after a normal pelvic ultrasonographic examination. A cystic left adnexal mass, 45 mm in diameter was discovered one year later. Pelvic examination revealed a tender, mobile, 4-5 cm. cul de sac mass. Endometrial thickness was reported as 10 mm on transvaginal ultrasonography. No tissue was obtained at endometrial biopsy. Tumor markers including CA 125 were in normal range. At laparotomy, a 5 cm unruptured, regular shape left ovarian cyst was found. Cyst was ruptured during dissection from the adjacent bowel. The patient underwent total abdominal hysterectomy, bilateral oophorectomy, bilateral pelvic and paraaortic lymph node sampling and infracolic omentectomy after frozen section of the left ovarian mass revealed borderline endometrioid tumor.

On histological examination, tumor was composed of atypical adenoid glands with back to back appearance resembling endometrial tissue. Areas of squamous differentiation and ciliary metaplasia and hobnail appearance were also observed (Figure 1). Small foci of endometriosis with macrophages filled with hemosiderin were seen (Figu-
Discussion

Tamoxifen is a unique drug which has surprising effects on the female genital system. Its main effect is anti-estrogenism and for this reason it is widely used in the treatment of breast cancer. It also exerts beneficial effect on bone, on cholesterol preventing fatal myocardial infarction and osteoporosis (6). In postmenopausal patients where estrogentic environment is extremely low, it may exert weak estrogentic stimulus on endometrium. Endometrial hyperplasia, polyps, even cancer are reported with prolonged tamoxifen exposure. Transvaginal ultrasound examination reveals abnormalities in the endometrium and the adjacent myometrium (7).

Tamoxifen is also reported to be an ovulation induction agent and can be a treatment option in clomiphene resistant patients (8). In premenopausal women, especially at the beginning of the treatment, simple functional cysts in the ovaries may appear. These cysts will disappear in the following several months.

A pelvic mass in a postmenopausal woman with a known history of endometriosis may arise the suspicion of malignant transformation of these foci. Demonstration of both cancerous and benign endometrial tissues in the same ovary, demonstration of cancer arising in the tissue and not invading it from another source and presence of endometrial stroma surrounding typical epithelial glands are the histological criteria for a diagnosis of a malignancy arising from endometriosis (9). Destruction of the tissue of origin by the adjacent tumor eliminates the histopathologic evidence of endometriosis in most of the cases (10). Macrophages with hemosiderin provide an additional support. The most frequent malignancy seen to arise in endometriosis is endometrioid adenocarcinomas (11). Sarcomas and mixed mesodermal tumors may be also seen. Endometriosis and endometrioid adenocarcinomas have been reported to contain estrogen and progesteron receptor activity (12).

The signs and symptoms of endometriosis usually regress after the menopause and its low estrogentic environment ensues. Estrogen replacement therapy may aggravate the endometriosis foci, so even in hysterectomized women progestins should be added to the treatment for at least six months. Some authors advocate a short course of progestin, danazol or gonadotropin releasing analog treatment (3-6 months) to suppress the residual endometriosis before the hormonal replacement therapy with estrogen and progesterone (9). There are reports of reactivation of endometriosis in postmenopausal women on tamoxifen (13). Tamoxifen, also increases myometrial volume and uterine size, probably associated reactivation of preexisting adenomyosis (14).

Endometrioid low malignant potential tumors of the ovary can be divided into two groups. Benign endometrioid
tumors with cytologically atypical epithelium are called proliferative endometrioid tumors (PET). If the tumor has more extensive atypical proliferative endometrium with a focus more than 5 mm in diameter is called endometrioid tumors of low malignant potential (ETLMP). It is reported that endometriosis was present in the pelvis, outside the ovary in 43 and 52% of PET and ETLMP respectively and in the same ovary in 100% and 69% respectively (15). Lower percentages were reported in some other articles (16). It is unclear how many neoplasms actually arise in endometriosis. It has been estimated around 5% of endometrioid carcinomas arise from endometriotic cysts (15).

In this presented case, we may just see a coincidence since exposure duration to tamoxifen is relatively short. The possibility of a metastasis from the previous breast cancer should be considered, but histologic architecture is clearly different. Tamoxifen which has weak estrogenic stimulus may act as a cancer promter in the endometriotic foci in postmenopausal patients. Therefore, ovaries, besides endometrium, should be thoroughly observed during tamoxifen treatment.

REFERENCES